Open Access

MicroRNA‑198 suppresses prostate tumorigenesis by targeting MIB1

  • Authors:
    • Jessica Ray
    • Christianne Hoey
    • Xiaoyong Huang
    • Jouhyun Jeon
    • Samira Taeb
    • Michelle R. Downes
    • Paul C. Boutros
    • Stanley K. Liu
  • View Affiliations

  • Published online on: July 15, 2019     https://doi.org/10.3892/or.2019.7234
  • Pages: 1047-1056
  • Copyright: © Ray et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MicroRNAs are small non‑coding RNA molecules which act as modulators of gene function, and have been identified as playing important roles in cancer as both tumor suppressors and oncogenes. The present study aimed to examine the role of miR‑198 in prostate cancer aggression by analyzing how it influences several hallmarks of cancer. Abundance of miR‑198 in prostate cancer and association with clinical characteristics was analyzed using a CPC‑Gene prostate cancer dataset. Overexpression of miR‑198 was performed using transient transfection of miR‑198 mimic prior to assaying proliferation, cell cycle, and colony formation in LNCaP and DU145 cell lines using standard protocols. In vivo tumor formation in athymic nude mice was examined using LNCaP xenografts with stable overexpression conferred using lentiviral miR‑198 transduction. Protein and mRNA abundance of MIB1 was determined using western blotting and RT‑qPCR respectively, while miR‑198 binding to MIB1 was validated using a luciferase reporter assay. miR‑198 abundance was lower in high Gleason grade prostate cancer relative to intermediate and low‑grade cancer. Overexpression of miR‑198 diminished proliferation of prostate cancer cell lines, increased G0/G1 cell cycle arrest, and significantly impaired colony formation. Elevated miR‑198 abundance was also demonstrated to impair tumor formation in vivo using LNCaP xenografts. Mindbomb E3 ubiquitin protein ligase 1 (MIB1) was demonstrated to be directly targeted by miR‑198, and knockdown of MIB1 recapitulated the effects of miR‑198 on proliferation and colony formation. The present evidence supports miR‑198 as an important tumor suppressor in prostate cancer, and demonstrates for the first time that it acts by targeting MIB1. The present study reinforces the importance and complexity of miRNA in regulating prostate cancer aggression.

References

1 

Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, Meng A, Hennings-Yeomans PH, McPherson A, Sabelnykova VY, et al: Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 47:736–745. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, et al: Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 541:359–364. 2017. View Article : Google Scholar : PubMed/NCBI

3 

Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI

4 

Bi C, Chung TH, Huang G, Zhou J1, Yan J, Ahmann GJ, Fonseca R and Chng WJ: Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. Oncotarget. 6:26508–26518. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Cui Z, Zheng X and Kong D: Decreased miR-198 expression and its prognostic significance in human gastric cancer. World J Surg Oncol. 14:332016. View Article : Google Scholar : PubMed/NCBI

6 

Hu Y, Tang Z, Jiang B, Chen J and Fu Z: miR-198 functions as a tumor suppressor in breast cancer by targeting CUB domain-containing protein 1. Oncol Lett. 13:1753–1760. 2017. View Article : Google Scholar : PubMed/NCBI

7 

Huang WT, Wang HL, Yang H, Ren FH, Luo YH, Huang CQ, Liang YY, Liang HW, Chen G and Dang YW: Lower expressed miR-198 and its potential targets in hepatocellular carcinoma: A clinicopathological and in silico study. Onco Targets Ther. 9:5163–5180. 2016. View Article : Google Scholar : PubMed/NCBI

8 

Marin-Muller C, Li D, Bharadwaj U, Li M, Chen C, Hodges SE, Fisher WE, Mo Q, Hung MC and Yao Q: A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer. Clin Cancer Res. 19:5901–5913. 2013. View Article : Google Scholar : PubMed/NCBI

9 

Nie E, Jin X, Wu W, Yu T, Zhou X, Shi Z, Zhang J, Liu N and You Y: MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT. J Neurooncol. 133:59–68. 2017. View Article : Google Scholar : PubMed/NCBI

10 

Wang M, Wang J, Kong X, Chen H, Wang Y, Qin M, Lin Y, Chen H, Xu J, Hong J, et al: MiR-198 represses tumor growth and metastasis in colorectal cancer by targeting fucosyl transferase 8. Sci Rep. 4:61452014. View Article : Google Scholar : PubMed/NCBI

11 

Wu S, Zhang G, Li P, Chen S, Zhang F, Li J, Jiang C, Chen X, Wang Y, Du Y, et al: miR-198 targets SHMT1 to inhibit cell proliferation and enhance cell apoptosis in lung adenocarcinoma. Tumour Biol. 37:5193–5202. 2016. View Article : Google Scholar : PubMed/NCBI

12 

Zhang S, Zhao Y and Wang L: MicroRNA-198 inhibited tumorous behaviors of human osteosarcoma through directly targeting ROCK1. Biochem Biophys Res Commun. 472:557–565. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Liu SK, Bham SA, Fokas E, Beech J, Im J, Cho S, Harris AL and Muschel RJ: Delta-like ligand 4-notch blockade and tumor radiation response. J Natl Cancer Inst. 103:1778–1798. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

15 

Dweep H, Sticht C, Pandey P and Gretz N: miRWalk-database: Prediction of possible miRNA binding sites by ‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847. 2011. View Article : Google Scholar : PubMed/NCBI

16 

Mork CN, Faller DV and Spanjaard RA: Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide. FEBS Lett. 581:5440–5444. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Itoh M, Kim CH, Palardy G, Oda T, Jiang YJ, Maust D, Yeo SY, Lorick K, Wright GJ, Ariza-McNaughton L, et al: Mind bomb is a ubiquitin ligase that is essential for efficient activation of Notch signaling by Delta. Dev Cell. 4:67–82. 2003. View Article : Google Scholar : PubMed/NCBI

18 

Ye L, Li S, Ye D, Yang D, Yue F, Guo Y, Chen X, Chen F, Zhang J and Song X: Livin expression may be regulated by miR-198 in human prostate cancer cell lines. Eur J Cancer. 49:734–740. 2013. View Article : Google Scholar : PubMed/NCBI

19 

Deng G, Ma L, Meng Q, Ju X, Jiang K, Jiang P and Yu Z: Notch signaling in the prostate: Critical roles during development and in the hallmarks of prostate cancer biology. J Cancer Res Clin Oncol. 142:531–547. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Su Q and Xin L: Notch signaling in prostate cancer: Refining a therapeutic opportunity. Histol Histopathol. 31:149–157. 2016.PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 42 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ray, J., Hoey, C., Huang, X., Jeon, J., Taeb, S., Downes, M.R. ... Liu, S.K. (2019). MicroRNA‑198 suppresses prostate tumorigenesis by targeting MIB1. Oncology Reports, 42, 1047-1056. https://doi.org/10.3892/or.2019.7234
MLA
Ray, J., Hoey, C., Huang, X., Jeon, J., Taeb, S., Downes, M. R., Boutros, P. C., Liu, S. K."MicroRNA‑198 suppresses prostate tumorigenesis by targeting MIB1". Oncology Reports 42.3 (2019): 1047-1056.
Chicago
Ray, J., Hoey, C., Huang, X., Jeon, J., Taeb, S., Downes, M. R., Boutros, P. C., Liu, S. K."MicroRNA‑198 suppresses prostate tumorigenesis by targeting MIB1". Oncology Reports 42, no. 3 (2019): 1047-1056. https://doi.org/10.3892/or.2019.7234